OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Medicinal Chemistry is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Oxidative stress mitigation by antioxidants - An overview on their chemistry and influences on health status	321
Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview	267
Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review	230
β-lactam antibiotics: An overview from a medicinal chemistry perspective	228
Alzheimer’s disease and its treatment by different approaches: A review	200
An insight on medicinal attributes of 1,2,4-triazoles	163
Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: A review	156
RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic	136
Application of sulfoximines in medicinal chemistry from 2013 to 2020	133
A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer’s disease agents: A review	127
Bioactive pyrrole-based compounds with target selectivity	126
hERG toxicity assessment: Useful guidelines for drug design	124
The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020	116
Antibacterial activities with the structure-activity relationship of coumarin derivatives	116
Research progress of mTOR inhibitors	114
Design and discovery of boronic acid drugs	113
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges	110
Small molecule selenium-containing compounds: Recent development and therapeutic applications	108
Anticancer property of ginsenoside Rh2 from ginseng	104
The importance of indole and azaindole scaffold in the development of antitumor agents	97
Chalcone hybrids as privileged scaffolds in antimalarial drug discovery: A key review	97
Indole-based derivatives as potential antibacterial activity against methicillin-resistance Staphylococcus aureus (MRSA)	92
Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation	91
In vitro and in vivo anticancer activity of tridentate thiosemicarbazone copper complexes: Unravelling an unexplored pharmacological target	84
Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease	84

Synthetic and medicinal perspective of quinolines as antiviral agents	83
Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine	79
Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation	79
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir	77
Treatment for liver cancer: From sorafenib to natural products	76
Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors	75
Recent advance on PTP1B inhibitors and their biomedical applications	75
A review: Pharmacological aspects of metal based 1,2,4-triazole derived Schiff bases	74
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes	72
Current development of CBP/p300 inhibitors in the last decade	72
Recent advancements in the development of bioactive pyrazoline derivatives	72
Discovery of natural anti-inflammatory alkaloids: Potential leads for the drug discovery for the treatment of inflammation	71
PROTACs to address the challenges facing small molecule inhibitors	70
A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery	70
1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA)	70
Current scenario of indole derivatives with potential anti-drug-resistant cancer activity	69
The application of isatin-based multicomponent-reactions in the quest for new bioactive and druglike molecules	69
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity	68
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review	67
Recent accomplishments on the synthetic/biological facets of pharmacologically active 1H-1,2,3-triazoles	66
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer	66
Developments of CRBN-based PROTACs as potential therapeutic agents	66
Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise	65
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application	65
Antimicrobial drugs bearing guanidine moieties: A review	64
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment	64
Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1	63
A review: Biologically active 3,4-heterocycle-fused coumarins	63
Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective	63
Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019)	62
A review on the structure and pharmacological activity of phenylethanoid glycosides	62
Chemotherapy and chemo-resistance in nasopharyngeal carcinoma	62
Azithromycin: The First Broad-spectrum Therapeutic	62
Quercetin derivatives: Drug design, development, and biological activities, a review	62
Recent advancements in the development of heterocyclic anti-inflammatory agents	61
Activity-based protein profiling: Recent advances in medicinal chemistry	61
Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update	61
Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect	61